Precipio Ships First IV-Cell® Order to Major US Healthcare System
21. März 2023 10:30 ET
|
Precipio, Inc.
NEW HAVEN, Conn., March 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) delivered its first order of IV-Cell®, the Company’s proprietary cytogenetics...
Precipio & ADS Biotec Sign Global Distribution Agreement for IV-Cell™
20. August 2020 13:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has signed an exclusive global distribution agreement with ADS...
Precipio Signs Exclusive Manufacturing Agreement for IV-Cell™
04. Juni 2019 09:10 ET
|
Precipio, Inc.
NEW HAVEN, Conn., June 04, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing...
Precipio Conducts IV-Cell™ Validation Trial with a Prominent Laboratory
06. Mai 2019 09:20 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 06, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of completing a trial of its Proprietary IV-Cell...